Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of Gardasil in adolescents vaccinated at 9-18 years of age
2014-005717-23Phase 3
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of qHPV vaccine in human papillomavirus infection, sponsored by Merck & Co. Primary endpoints: Anti-HPV 6, 11, 16, and 18 antibody levels up to 10 years after dose 3, Long-term effectiveness in girls and 1 more.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2014-005717-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005717-23.